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T
he devastating effects of HIV 
infection worldwide are reason 
enough for AIDS researchers to 
grasp at thin rays of hope. But seldom 
has a single anecdotal case stimulated 
as much hope as the 1999 report 
of an acutely infected patient who 
appeared to control HIV replication 
after two short treatment interruptions 
[1]. This report generated the 
hypothesis that early antiretroviral 
treatment (during or very soon after 
symptomatic seroconversion) allows the 
incompletely damaged immune system 
to recover and respond appropriately 
to virus antigens during treatment 
interruptions. This, in turn, according 
to the hypothesis, leads to control 
of viral replication by a healed and 
appropriately stimulated immune 
response to the patient’s HIV infection. 
Consistent with this hypothesis 
was the prior ﬁ  nding that early 
antiretroviral therapy led to induction 
of HIV-speciﬁ  c proliferative responses 
similar to those that had been 
observed in patients with long-term, 
non-progressing HIV [2]. This led 
Rosenberg and colleagues to ask 
whether HIV-speciﬁ  c proliferative 
responses were a necessary and 
sufﬁ  cient cause of long-term non-
progression or just an immunologic 
consequence of controlled virus 
replication. Their report of virologic 
control in patients who interrupted 
therapy after early treatment raised 
hope that if HIV infection was treated 
early enough, the immune system 
could be repaired sufﬁ  ciently to allow 
for long-term immunologic control of 
HIV replication [3]. Unfortunately, 
that’s where the good news ends.
Enthusiasm Fades
A series of discoveries from clinical 
trials began to chip away at the 
enthusiasm for both early treatment of 
HIV infection and supervised treatment 
interruptions (STIs) as a way to boost 
the immune response. 
Several small trials of STIs in 
chronically infected patients were 
carried out [4], buoyed by the 
reasonable desire of patients for respite 
from the unpleasant side effects of the 
drugs. These trials gave disappointing 
results, up to and including the 
emergence of antiretroviral drug 
resistance in patients randomized to 
receive STIs. HIV-speciﬁ  c immune 
responses did increase off therapy, 
but so did viral loads. The so-called 
immune boosting probably reﬂ  ected 
an immune response to greater viral 
antigen load but did not represent 
constructive immune enhancement. 
Larger trials clearly showed that STIs 
were of little if any beneﬁ  t in chronic 
infection and that when therapy was 
stopped, viral loads invariably returned 
to pre-treatment levels [5]. Other 
studies indicated that HIV-speciﬁ  c 
CD4+ T cells were being preferentially 
infected, often massively, during 
treatment interruptions [6], and that 
proliferative responses were more likely 
to be a consequence—rather than a 
cause—of decreased HIV replication 
[7]. Despite multiple attempts, early 
reports of an inverse correlation 
between simple HIV-speciﬁ  c T cell 
responses and virologic control were 
not conﬁ  rmed [8]. Where complex 
T cell functions did show such a 
correlation, the data indicated that 
viral replication was adversely affecting 
the character of the T cell immune 
response to HIV, and not the other 
way around [9]. Thus, no evidence 
of “immune boosting” during STIs 
and subsequent viral control in the 
absence of antiretroviral drugs was ever 
established. Finally, one of the acutely 
treated patients within Rosenberg’s 
cohort became superinfected with 
a second strain of HIV despite 
excellent control of viral replication 
and signiﬁ  cant recognition of the 
superinfecting strain by the pre-existing 
T cell response [10].
New Findings
Now comes a study in this month’s PLoS 
Medicine that found that in 14 patients 
who were treated early and who had 
controlled viral loads for at least 90 
days, the virologic control was only 
transient [11]. While one could look at 
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this as a glass half full—these patients 
achieved a reasonable period of time 
off antiretroviral therapy—closer 
scrutiny of the data limits this view. 
There was a disconnect between the 
low viral loads and an unexpectedly 
high rate of CD4+ T cell decline 
in several patients. While the small 
number of patients and the single-arm 
nature of the study preclude deﬁ  nitive 
comparisons, it is possible that the early 
treatment and STIs did not result in 
a delay in CD4+ T cell decline (and, 
therefore, initiation of antiretroviral 
therapy) beyond what would have 
occurred had the patients received no 
early treatment.
Implications of the Study
This study raises important questions 
in our understanding of HIV 
pathogenesis, treatment, and vaccine 
development. 
First, why is it that early antiretroviral 
treatment, even if it does lead to better 
control of viral replication, does not 
protect against CD4+ T cell depletion? 
It is possible that by the time patients 
present with acute retroviral syndrome 
their CD4+ T cell reserves (in gut and 
lymphoid tissues) have been severely 
depleted, despite the fairly normal 
CD4+ proﬁ  le of their peripheral blood. 
Thus, even low-level viral replication 
is then sufﬁ  cient to deplete the 
remaining central and peripheral 
reserves [12]. 
Second, how do these ﬁ  ndings 
affect treatment guidelines during 
acute infection? None of the current 
treatment guidelines in either 
resource-rich or resource-poor settings 
recommend early antiretroviral 
therapy. In the light of these new 
data [11], there does not appear to 
be a rationale for early antiretroviral 
therapy in the absence of a clinical 
trial to assess other interventions in 
concert with early therapy. The use of 
therapeutic vaccination is an obvious 
intervention that still needs to be 
tested, despite limited efﬁ  cacy results 
in treated chronic infection. As such, 
practice guidelines should continue to 
caution against early treatment unless 
associated with a randomized clinical 
trial.
Finally, is this good or bad news for 
HIV vaccine development? Since most 
current vaccine strategies are based 
upon the hypothesis that induction 
of T cell immunity will lead to control 
of viral replication, it is difﬁ  cult to be 
optimistic when a strong and broad 
immune response is unable to prevent 
disease progression. However, one must 
recall that phenotypic and functional 
assessments of HIV-speciﬁ  c T cell 
responses, even in antiretroviral-treated 
patients, show that these responses 
clearly differ from responses against 
viruses that are normally cleared or 
controlled by the immune system [9]. 
Therefore, the T cell responses in the 
patients treated for acute HIV infection 
in Kaufmann et al.’s study were 
induced upon a dramatically altered 
immune background. It remains to be 
determined how much this adversely 
affects the HIV-speciﬁ  c immune 
response, and whether an immune 
response generated by vaccination before 
any HIV replication (a prophylactic 
vaccine) might be better able to control 
virus replication. Far be it for us to stop 
grasping at rays of hope.  
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